Oral & Macrocyclic Peptides – Part 1
Advancing the Frontier of Peptide Therapeutics
4/20/2027 - April 21, 2027 ALL TIMES PDT
Cambridge Healthtech Institute's Oral & Macrocyclic Peptides conferences (parts 1 & 2) are among the few peptide therapeutics conferences devoted to chemistry. The cornerstone of this two-part meeting is oral and/or macrocyclic peptide design and discovery, reflecting the next generation of peptide therapeutics and this conference's claim to fame as the industry's first macrocyclic-focused conference. However, peptide chemistry with broad peptide drug discovery and development implications, such as those spurred by the flurry of GLP1-related peptide activity, and downstream peptide development, will also be considered because the industry's frontier of peptide chemistry is relatively new and the scientists as well as the molecules are advancing together. Join us for this recently expanded two-part program to share progress, challenges, and solutions among leading medicinal and drug development peptide chemists, who are often one and the same (unlike the case for small molecules).
Preliminary Agenda

MACROCYCLIC INHIBITORS

Novel Macrocyclic Molecular Glue Modulators of STAT6 with Differentiated Pharmacology

Photo of Rick Ewing, PhD, Vice President and Head of Chemistry, Rapafusyn Pharmaceuticals , Vice President , Chemistry , Rapafusyn Pharmaceuticals
Rick Ewing, PhD, Vice President and Head of Chemistry, Rapafusyn Pharmaceuticals , Vice President , Chemistry , Rapafusyn Pharmaceuticals

RapaGlues are Cooperative Molecular Glue Modulators with utility in targeting hard to drug proteins, targets with selectivity challenges or targets where small molecules don’t capture the full efficacy potential.  Herein we will discuss the properties of RapaGlues, success rate against a wide range of target classes and a case study on STAT6 modulation.  RapaGlue modulators of STAT6 display pharmacology beyond what is known for small molecule inhibitors and have potential for best in class profile.

Drugging Cyclin A/B Protein–Protein Interactions with Orally Bioavailable Macrocycles: From Structure-Guided Design to Clinical Translation

Photo of Peadar Cremin, PhD, Executive Director & Head of DMPK, Clinical Pharmacology & Toxicology, Circle Pharma Inc. , Executive Director & Head of DMPK , Clinical Pharmacology & Toxicology , Circle Pharma Inc
Peadar Cremin, PhD, Executive Director & Head of DMPK, Clinical Pharmacology & Toxicology, Circle Pharma Inc. , Executive Director & Head of DMPK , Clinical Pharmacology & Toxicology , Circle Pharma Inc

Potent Macrocyclic Peptide Ligands Against Transcription Factors

Photo of Scott Lokey, PhD, Professor, Chemistry and Biochemistry, University of California, Santa Cruz , Professor , Chemistry & Biochemistry , University of California, Santa Cruz
Scott Lokey, PhD, Professor, Chemistry and Biochemistry, University of California, Santa Cruz , Professor , Chemistry & Biochemistry , University of California, Santa Cruz

CYCLIC PEPTIDE DISCOVERY, DESIGN, OR OPTIMIZATION

Bead-Based mRNA Display for Macrocyclic Libraries

Photo of Brian M. Paegel, PhD, Professor, Pharmaceuticals Sciences, University of California, Irvine , Professor , Pharmaceuticals Sciences , University of California, Irvine
Brian M. Paegel, PhD, Professor, Pharmaceuticals Sciences, University of California, Irvine , Professor , Pharmaceuticals Sciences , University of California, Irvine

Cyclic Peptide Inhibitor Discovery by Coupling DNA-Encoded Cyclic Peptide Libraries with an AI-Based Generative Model

Photo of Xiaojie Bruce Lu, PhD, Professor & Principal Investigator, Chemical Biology Research Center, Chinese Academy of Sciences , Prof & Principal Investigator , Chemical Biology Research Ctr , SIMM, CAS
Xiaojie Bruce Lu, PhD, Professor & Principal Investigator, Chemical Biology Research Center, Chinese Academy of Sciences , Prof & Principal Investigator , Chemical Biology Research Ctr , SIMM, CAS

Cyclic peptide drug discovery has attracted wide attention with recent several drug approvals. Although DNA-encoded library has been widely applied for the cyclic peptide hit identification, the hit-to-lead optimization is still a significant challenge for the medicinal chemistry campaigns. This talk will discuss recent progress on integrating DNA-encoded focused library strategy with AI-based generative model to speed up the hit-to-lead optimization.


DNA-Encoded Peptide Libraries

Photo of Valerie Waser, PhD, Postdoctoral Fellow, Chemical Biology, Christian Heinis Lab, EPFL , Postdoctoral Fellow , Chemical Biology , EPFL
Valerie Waser, PhD, Postdoctoral Fellow, Chemical Biology, Christian Heinis Lab, EPFL , Postdoctoral Fellow , Chemical Biology , EPFL

DNA-encoded peptide libraries hold great promise for discovering membrane-permeable ligands against challenging therapeutic targets. However, the numerous consecutive coupling steps required for peptide synthesis often compromise library quality. We addressed this limitation by using short peptides rather than individual amino acids as building blocks. I will present our high-throughput approach for synthesizing hundreds of such building blocks and assembling them into large, high-quality DNA-encoded peptide libraries.

Conformational Control for Property Enhancement of Macrocycles

Photo of Felix Hausch, PhD, Professor Biochemistry, Structure Based Drug Discovery, Technical University of Darmstadt , Prof Biochemistry , Structure Based Drug Discovery , Technical Univ of Darmstadt
Felix Hausch, PhD, Professor Biochemistry, Structure Based Drug Discovery, Technical University of Darmstadt , Prof Biochemistry , Structure Based Drug Discovery , Technical Univ of Darmstadt

Macrocycles are nature’s preferred choices to generate large cell-permeable bioactive molecules. They are also increasingly considered as modalities for difficult-to-bind proteins but strategies to best exploit their potential are only beginning to emerge.Our results highlight linkers as an opportunity for macrocyclic drug development, show how linker derivatization can improve the performance of macrocycles, and emphasizes the need to track macrocyclic scaffold evolution at a three-dimensional level.

PLENARY

PLENARY KEYNOTE

The Druggable Transcriptome: From RNA Recognition to Precision Medicines

Matthew D. Disney, PhD, Institute Professor & Chair, UF Scripps Institute for Biomedical Innovation & Technology , Professor , Chemistry , Scripps Research Institute


For more details on the conference, please contact:
Anjani Shah, PhD
Senior Conference Director
Cambridge Healthtech Institute
(+1) 781-247-6252
Email: ashah@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com


Register Early for Maximum Savings

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides


Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners